In the offices of an early-stage biopharmaceutical developer, the team has received exciting news. Their early-phase advanced therapy trial, currently operating at just one clinical site, has earned investigators' interest and will expand faster than planned.
The Chief Medical Officer hopes to expand the trial to four clinical sites within 10 weeks. The initial site, located in a major city with two airports, runs smoothly. Leukapheresis takes place in the morning, allowing for rapid transfer of collected patient material to a nearby airport within hours. The clinical site is geographically close to the manufacturing site, meaning that the patients' cells are shipped to manufacturing overnight. Traceability and logistics have been run manually. Three patients have been treated, with a fourth patient journey in process.
This initial success raises the team's optimism as they consider the new clinical sites -two based in major metropolitan areas much farther away, and a third in a more rural location with one smaller, remote airport. There, leukapheresis will be performed at a local blood bank, not at the clinical site.
The therapy continues to change patients' lives. But as the trial tries to grow, operations falter, and the therapy never reaches patients at commercial scale. Why?
The company had secured funding, trained clinicians, and managed costs. But as the trial grew, its operators did not account for the complexity that scale brings. Moving therapies through multiple airports, time zones, hospital systems-plus the tracking challenges that emerged-became daunting. An efficacious and safe therapy couldn't reach more patients because the company had not understood the criticality of building a digitally scalable, traceable logistics platform.
CRITICAL LESSON: START WITH THE END STATE IN MIND
For long-term success, advanced therapies require a risk-based understanding of the supply chain with all aspects mapped early. Recent draft guidance from the U.S Food and Drug Administration on the use of expansion cohorts in first-in-human clinical trials for oncology drugs and biologics stresses early end-to-end systems thinking and data management capabilities. The draft guidance states "To… protect patients, it is imperative that sponsors establish an infrastructure to streamline trial logistics, facilitate data collection and incorporate plans to rapidly assess emerging data in real time and to disseminate interim results to investigators, institutional review boards (IRBs), and regulators."
As three pioneering leaders in advanced therapy operations and delivery, we present commercially-minded thinking on the use of clinical phases to create viable commercial supply chains and patient journeys from the beginning. While these lessons apply to a wide variety of advanced therapy indications, this article will focus most directly on oncology, currently the largest single indication being pursued [2] .
DEVELOPMENT PHASES IN ADVANCED THERAPIES
As part of a commercially-minded approach, it is also important to note that in biopharmaceutical Some of the activities in this "Build" phase are common in biopharmaceutical development, such as focus on scientific proof of concept and definition of the therapeutic product. Other activities reflect unique factors in advanced therapies. Through mechanisms such as the U.S. FDA's Regenerative Medicine Advanced Therapy Designation (RMAT), regulatory pathways and timelines may also be accelerated [5] . With high expectations from clinical partners, regulators and investors, speed is essential. Supporting systems that enable the continuous collaboration required in advanced therapies take on increased importance, and need to grow and adjust as lessons are learned in real-time.
In the "Build" phase, activities and planning for logistics platforms, digital supply chain management and other enabling technologies reflect this need for speed. While these systems may not yet need to scale out widely, they do need to support accelerated timelines as well as high expectations from clinical site investigators, Quality teams, investors and regulatory experts.
In oncology-focused advanced therapies, this "Operate" phase often involves a pivotal trial. Patient volume will continue to grow, and the number of clinical sites may also expand internationally. This phase offers an ideal time to actively prepare for commercialization and establish the underlying systems and protocols that will enable safety and efficiency at scale. For example, growing patient and site volumes often require active management of manufacturing capacity. This same growth often requires expanded logistics and supply chain management systems, ensuring that these systems have the flexibility to integrate both internally and externally. Amid this growth, biopharmaceutical developers may face pressure to begin locking their protocols, systems and SOPs, including those related to logistics and supply chain, as part of preparation for a regulatory application filing.
In the "Operate" phase, advance work on logistics platforms, digital supply chain management and other enabling systems repeatedly demonstrates a return on investment. If the necessary foundation has been designed thoughtfully and laid in advance, this phase points the way towards a fully-developed vision of commercial success.
This phase is the "dress rehearsal" for commercial launch. In the accelerated world of advanced therapies, this phase may sometimes be combined with Phase II ½ "Build." A range of stakeholders, including clinical investigators, regulators, and investors, expect visibility into a wide range of data, from expanded efficacy endpoints to systems' operations. Patient volume may continue to expand, with corresponding growth in complexity.
At the "Optimize" phase, underlying systems and processes, including those related to logistics and supply chain, will be tested, validated and then enter a semi-locked demonstration state for regulatory filings. Demonstrating mastery of COI/COC and COCn will be an essential part of the biologics application. [6] The "Optimize" phase also provides invaluable data that shows how the patient journey will work in the commercial world. Data management takes on new importance. Regulators are likely to require a complete data download of key actions that occurred on behalf of each "intent to treat" patient. Commercial teams will require data as they ramp up for a launch that will rely on order-to-cash and reimbursement processes, post-approval. In this phase, logistics systems, digital supply chain management and other enabling technologies should now be running in real time. Logistics is now a key concern and a fully formed logistics platform is required. A documented, validated digital supply chain management system is also a requirement, and internal integrations between a full range of e-systems should now be underway. Be ready to show how you will operate in the market. This impacts process development and enables investors and regulators to support the therapy.
Scaling becomes multi-dimensional

Lesson 2
Take your traceability and logistics platform as seriously as your science.
Create real, scalable integrations throughout the supply chain.
Develop the capability to operate logistics platform, COI/COC and COCn at volume COGS improvement requirements will start to kick in. New collaborations keep emerging.
Lesson 3
Regulators will expect solid systems, even early on. Seek out flexibility Ensure quality and compliance now, in ways that can scale efficiently
Regulators' expectations for numerous systems, including COI/COC, are increasingly set.
Success begets more demand, which will continue to pressure-test systems and processes.
Expert tip
Use Target Product Profiles to identify critical logistics attributes and assess their impact as the therapy scales. This produces a development pathway in-line with process development and gives confidence to investors that the therapy is a viable commercial proposition.
Work with proven logistics and supply chain partners to think proactively about workflows and apply proven solutions. Use critical parameters to start overcoming critical supply chain and logistics bottlenecks early, addressing the highest risks first. Design for scale, even if part of the process remains manual for now. Starting with some automation and keeping integrations simple will allow room for learning Don't underestimate the importance of this phase. While not necessarily part of traditional clinical phasing, this "Operate" period lays critical early groundwork for commercial-scale traceability and logistics platforms. This is a critical time for establishing scalable processes and systems to support commercialization-and patients.
Finalize your logistics platform and use that template to smoothly transfer into new geographies. Manage complexity from less experienced sites that will therefore need more support, placing a greater burden on the therapy developer.
Logistics can be a key differentiator and provide additional patient and provider value. Logistics and traceability platforms should be constantly reviewed and take internal and external changes into account, such as shipping volumes or political events.
f FIGURE 1
Advanced therapy clinical journey: the patient is the process and the product development, the nature of clinical phases is changing. In advanced therapies, that change is accelerated. Increasingly, clinical phasing doesn't conform neatly to the norms of "Phase I," "Phase II," "Phase III," and "Commercial Launch." We've often seen five phases emerge, rather than the traditional four, with some activities pulled forward earlier and new activities emerging. In this section, we outline our view of these five phases, with success factors for each.
CONCLUDING INSIGHTS
Advanced therapies face a pivotal moment. With more than 570 [7] oncology-focused advanced therapies in the discovery pipeline, now is the time for early-phase developers to benefit from lessons that accelerate patient journeys.
Here are final take-aways: Above all, seek input from industry experts who have been there before. Partners who you might typically call "vendors" are actually technical experts who have overcome the challenges you face. A large number of learnings already exist in this nascent industry. Working with the right partners to plan out development, scale logistics, and properly time e-systems, automation, and integrations will be a critical factor on the journey to commercial success.
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Using the principles of Logistics by Design we can help you create a logistics platform that will support you at both clinical and commercial scale. 
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